Switch theme
Sign up to access all valuation multiples
Youcare Pharmaceutical Group Co Ltd is a pharmaceutical group enterprise integrating new drug research and development, drug production, circulation and sales.
2001
n/a
LTM Revenue n/a
LTM EBITDA n/a
$893M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Youcare Pharmaceutical has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Youcare Pharmaceutical achieved revenue of $521M and an EBITDA of $52.7M.
Youcare Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Youcare Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $578M | $521M | XXX | XXX | XXX |
| Gross Profit | $405M | $362M | XXX | XXX | XXX |
| Gross Margin | 70% | 70% | XXX | XXX | XXX |
| EBITDA | $57.2M | $52.7M | XXX | XXX | XXX |
| EBITDA Margin | 10% | 10% | XXX | XXX | XXX |
| Net Profit | $46.2M | $25.5M | XXX | XXX | XXX |
| Net Margin | 8% | 5% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Youcare Pharmaceutical's stock price is CNY 16 (or $2).
Youcare Pharmaceutical has current market cap of CNY 7.3B (or $1.0B), and EV of CNY 6.5B (or $893M).
See Youcare Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $893M | $1.0B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Youcare Pharmaceutical has market cap of $1.0B and EV of $893M.
Youcare Pharmaceutical's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Youcare Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Youcare Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $893M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 16.9x | XXX | XXX | XXX |
| P/E | 58.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 81.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpYoucare Pharmaceutical's NTM/LTM revenue growth is n/a
Youcare Pharmaceutical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Youcare Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Youcare Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Youcare Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -8% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 33% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 51% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Youcare Pharmaceutical acquired XXX companies to date.
Last acquisition by Youcare Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Youcare Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Youcare Pharmaceutical founded? | Youcare Pharmaceutical was founded in 2001. |
| Where is Youcare Pharmaceutical headquartered? | Youcare Pharmaceutical is headquartered in China. |
| Is Youcare Pharmaceutical publicy listed? | Yes, Youcare Pharmaceutical is a public company listed on SHG. |
| What is the stock symbol of Youcare Pharmaceutical? | Youcare Pharmaceutical trades under 688658 ticker. |
| When did Youcare Pharmaceutical go public? | Youcare Pharmaceutical went public in 2020. |
| Who are competitors of Youcare Pharmaceutical? | Similar companies to Youcare Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Youcare Pharmaceutical? | Youcare Pharmaceutical's current market cap is $1.0B |
| What is the current revenue growth of Youcare Pharmaceutical? | Youcare Pharmaceutical revenue growth between 2023 and 2024 was -10%. |
| Is Youcare Pharmaceutical profitable? | Yes, Youcare Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
